Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07570446

AUTONOMOUS DISORDERS IN CMT

Hereditary neuropathies are a phenotypically and genetically heterogeneous group of disorders. One of the most common forms is Charcot-Marie-Tooth neuropathy (CMT), which can be further divided into demyelinating (CMT1) and axonal (CMT2) neuropathies, as well as various pathogenic genetic variants. In addition to the clinically predominant motor and sensory deficits, symptoms of the autonomic nervous system have also been described in patients with CMT, often leading to significant limitations in daily functioning and quality of life. However, little is known about the prevalence and extent of autonomic dysfunction in CMT patients.

In this study, patients with CMT will be assessed for the presence, severity, and characteristics of autonomic dysfunction using questionnaires and non-invasive diagnostic methods. Furthermore, diagnosis, genotype, and individual disease data-such as disease duration, severity of neurological impairment, and comorbidities-will be collected from patient records.

The aim of this study is to evaluate and characterize autonomic dysfunction in patients with CMT. It seeks to determine how frequently autonomic dysfunction occurs in CMT, which areas of the autonomic nervous system are most commonly affected, whether risk factors exist, and what differences can be observed between the various CMT subtypes. The findings of this study are expected to provide new insights into the role of autonomic dysfunction in CMT, ultimately contributing to improved care and treatment for affected patients.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical CMT Diagnosis / Anamnestically Healthy Control Group
  • Genetic confirmation of CMT in adult patients
  • Ability to achieve the outcome measure at baseline
  • Age between 18 and 65 years
  • Capacity of all study participants to consent and signed informed consent, - including patient or participant information and consent form

Exclusion criteria

  • Pregnancy or breastfeeding period
  • Other relevant neurological or psychiatric disorders, acute or in the past history
  • Presence of a serious previous internal disease

Treatment and study plan

Primary outcomes

  1. COMPASS 31

    Time frame: baseline

    validated questionaire

  2. electrophysiological measurement

    Time frame: baseline

    Validated electrophysiological examinations including the sympathetic skin reflex, the Schellong test, and heart rate variability measurement

Secondary outcomes

  1. muscle strength

    Time frame: baseline

  2. neurography

    Time frame: baseline

    Examinations measuring the electrical activity and conductivity of nerves, which are used to diagnose nerve damage or diseases.

  3. nerve sonography

    Time frame: at visit

Study contacts

Contact information is provided by the study sponsor or research team.

Michael W Sereda, Prof. MD

CONTACT

[email protected]

+49 551 3964162

Sponsors and collaborators

Lead sponsor

University Medical Center Goettingen

Other

Registry information

Acronym: CMT-autonom

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
May 6, 2026
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.